During a routine health maintenance visit, a 58-year-old male with essential hypertension and chronic kidney disease stage 2 is prescribed lisinopril. His blood pressure in the clinic is 152/94 mmHg. Baseline laboratory studies obtained today show a serum creatinine of 1.2 mg/dL and a serum potassium of 4.3 mEq/L. The patient is instructed on how to take the medication and asked to schedule a follow-up visit. Which of the following is the most appropriate next step in monitoring this patient's new therapy?
- Assess serum creatinine and potassium levels in 1 to 2 weeksAnswer
- BWait to assess serum potassium and creatinine only if the patient develops signs of fluid overload
- COrder a renal ultrasound immediately to screen for bilateral renal artery stenosis
- DMeasure prothrombin time and international normalized ratio at the next monthly visit
- EInitiate daily potassium supplementation and check an electrolyte panel in 3 months
Answer
Assess serum creatinine and potassium levels in 1 to 2 weeks
ACE inhibitors (such as lisinopril) reduce angiotensin II levels, leading to vasodilation of the efferent arteriole in the glomerulus. While this offers long-term renal protection, it can cause an acute, transient drop in the glomerular filtration rate (GFR) and a subsequent rise in serum creatinine. Furthermore, the resulting decrease in aldosterone production can lead to potassium retention. Therefore, standard medical guidelines require rechecking serum creatinine and potassium 1 to 2 weeks after initiating or increasing the dose of an ACE inhibitor or angiotensin receptor blocker (ARB). An asymptomatic increase in creatinine of up to 30% is generally acceptable, but larger increases or severe hyperkalemia may necessitate discontinuing the drug.
Step-by-Step Solution
Key Concept
ACE inhibitors require monitoring of a basic metabolic panel (specifically serum creatinine and potassium) within 1 to 2 weeks of initiation or dose titration to evaluate for acute kidney injury and hyperkalemia.